Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer

Abstract

Lung cancer is difficult to treat with a poor prognosis and a five year survival of 15%. Current molecularly targeted therapies are initially effective in non-small cell lung cancer (NSCLC) patients; however, they are plagued with difficulties including induced resistance and small therapeutically responsive populations. This mini review describes the… (More)

Topics

1 Figure or Table